FindTrial
Sign In

nab-paclitaxel and gemcitabine

DRUG6 trials

Sponsors

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, PrECOG, LLC., AIO-Studien-gGmbH, GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., Trishula Therapeutics, Inc.

Conditions

Adenocarcinoma of the PancreasAdvanced Pancreatic CancerCastration-resistant Prostate CancerCholangiocarcinomaDuctal Adenocarcinoma of PancreasEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastric Adenocarcinoma

Phase 1

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
TerminatedNCT04060342
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Castration-resistant Prostate Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma +11
Start: 2019-08-13End: 2022-04-11Updated: 2022-08-18
A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Active, not recruitingNCT07777211
Beijing Gene Key Life Technology Co., LtdAdvanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas
Start: 2025-08-14End: 2027-08-31Target: 52Updated: 2026-08-20

Phase 2

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
CompletedNCT02043730
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerentePancreatic Cancer Stage II
Start: 2014-01-31End: 2019-01-14Updated: 2019-10-09
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
CompletedNCT02181634
PrECOG, LLC.Cholangiocarcinoma
Start: 2014-12-09End: 2017-10-01Updated: 2018-10-03
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
CompletedNCT02564146
AIO-Studien-gGmbHAdenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer
Start: 2016-12-31End: 2022-05-31Updated: 2022-11-22
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
CompletedNCT06119217
Trishula Therapeutics, Inc.Pancreatic Cancer
Start: 2024-03-25End: 2026-03-06Updated: 2026-05-13

Related Papers

Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
2024-08-165 citations
Alternating application of gemcitabine/<i>nab</i>-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).
Journal of Clinical Oncology2024-01-202 citations
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
2021-08-0136 citations
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
BMC Cancer2021-07-1610 citations
Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).
Journal of Clinical Oncology2021-05-2010 citations
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
2021-03-3115 citations
388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
Regular and Young Investigator Award Abstracts2020-11-011 citations
389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2020-11-01
Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)
Cancer Research2020-08-152 citations
A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
Journal of Clinical Oncology2020-05-209 citations
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma
JAMA Oncology2018-09-03119 citations
PrE0204: A multi-institutional, single arm, two-stage phase II trial of nab-paclitaxel and gemcitabine for first-line treatment of patients with advanced or metastatic cholangiocarcinoma—A PrECOG LLC study.
Journal of Clinical Oncology2017-05-20